NASDAQ:MGTA Magenta Therapeutics Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Magenta Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.72 -0.31 (-3.86 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$7.47Now: $7.72▼$8.2350-Day Range$6.52MA: $7.15▼$8.1652-Week Range$5.76Now: $7.72▼$16.19Volume773,658 shsAverage Volume233,355 shsMarket Capitalization$372.51 millionP/E RatioN/ADividend YieldN/ABeta2.62 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingMagenta Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $19.00, Magenta Therapeutics has a forecasted upside of 146.1% from its current price of $7.72.Amount of Analyst CoverageMagenta Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesMagenta Therapeutics has received 130 “outperform” votes. (Add your “outperform” vote.)Underperform VotesMagenta Therapeutics has received 182 “underperform” votes. (Add your “underperform” vote.)Community SentimentMagenta Therapeutics has received 58.33% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Magenta Therapeutics and other stocks. Vote “Outperform” if you believe MGTA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MGTA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldMagenta Therapeutics does not currently pay a dividend.Dividend GrowthMagenta Therapeutics does not have a long track record of dividend growth. Previous Next 4.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Magenta Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,000,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 17.96% of the stock of Magenta Therapeutics is held by insiders.Percentage Held by Institutions61.41% of the stock of Magenta Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Magenta Therapeutics are expected to decrease in the coming year, from ($1.96) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Magenta Therapeutics is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Magenta Therapeutics is -3.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMagenta Therapeutics has a P/B Ratio of 2.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 4.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.92 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MGTA Previous Symbol CUSIPN/A CIKN/A Webwww.magentatx.com Phone857-242-0170Debt Debt-to-Equity RatioN/A Current Ratio17.35 Quick Ratio17.35Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.62 per share Price / Book2.13Profitability EPS (Most Recent Fiscal Year)($2.07) Net Income$-76,770,000.00 Net MarginsN/A Return on Equity-55.36% Return on Assets-49.45%Miscellaneous Employees59 Outstanding Shares48,253,000Market Cap$372.51 million Next Earnings Date11/11/2020 (Estimated) OptionableNot Optionable $7.72 -0.31 (-3.86 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive MGTA News and Ratings via Email Sign-up to receive the latest news and ratings for MGTA and its competitors with MarketBeat's FREE daily newsletter. Magenta Therapeutics (NASDAQ:MGTA) Frequently Asked Questions How has Magenta Therapeutics' stock been impacted by Coronavirus (COVID-19)? Magenta Therapeutics' stock was trading at $9.16 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, MGTA stock has decreased by 15.7% and is now trading at $7.72. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Magenta Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Magenta Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Magenta Therapeutics. When is Magenta Therapeutics' next earnings date? Magenta Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020. View our earnings forecast for Magenta Therapeutics. How were Magenta Therapeutics' earnings last quarter? Magenta Therapeutics Inc (NASDAQ:MGTA) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.06. View Magenta Therapeutics' earnings history. What price target have analysts set for MGTA? 4 equities research analysts have issued 1 year target prices for Magenta Therapeutics' shares. Their forecasts range from $15.00 to $22.00. On average, they anticipate Magenta Therapeutics' share price to reach $19.00 in the next year. This suggests a possible upside of 146.1% from the stock's current price. View analysts' price targets for Magenta Therapeutics. Are investors shorting Magenta Therapeutics? Magenta Therapeutics saw a increase in short interest during the month of August. As of August 14th, there was short interest totaling 1,550,000 shares, an increase of 13.1% from the July 30th total of 1,370,000 shares. Based on an average daily trading volume, of 323,300 shares, the short-interest ratio is currently 4.8 days. Approximately 5.3% of the shares of the stock are short sold. View Magenta Therapeutics' Short Interest. Who are some of Magenta Therapeutics' key competitors? Some companies that are related to Magenta Therapeutics include Ligand Pharmaceuticals (LGND), Heron Therapeutics (HRTX), Dicerna Pharmaceuticals (DRNA), ZEALAND PHARMA/S (ZEAL), Rocket Pharmaceuticals (RCKT), Arcus Biosciences (RCUS), Intercept Pharmaceuticals (ICPT), ALX Oncology (ALXO), Generation Bio (GBIO), Trillium Therapeutics (TRIL), Epizyme (EPZM), Amneal Pharmaceuticals (AMRX), Zogenix (ZGNX), Akero Therapeutics (AKRO) and Rhythm Pharmaceuticals (RYTM). View all competitors. What other stocks do shareholders of Magenta Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Magenta Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Myovant Sciences (MYOV), NVIDIA (NVDA), ADMA Biologics (ADMA), Nabriva Therapeutics (NBRV), Amarin (AMRN), Canopy Growth (CGC) and Crispr Therapeutics (CRSP). Who are Magenta Therapeutics' key executives? Magenta Therapeutics' management team includes the following people: Mr. Jason Gardner, Co-Founder, CEO, Pres & Director (Age 48)Mr. Michael P. Cooke, Chief Scientific Officer (Age 57)Ms. Alison Lawton, Board Advisor (Age 58)Mr. Jason Ryan, Chief Operating & Financial Officer (Age 45)Ms. Manisha Pai, VP of Investor Relations & Communications When did Magenta Therapeutics IPO? (MGTA) raised $100 million in an IPO on Thursday, June 21st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. What is Magenta Therapeutics' stock symbol? Magenta Therapeutics trades on the NASDAQ under the ticker symbol "MGTA." Who are Magenta Therapeutics' major shareholders? Magenta Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Gilder Gagnon Howe & Co. LLC (8.98%), Artal Group S.A. (0.93%), Luminus Management LLC (0.74%), Platinum Investment Management Ltd. (0.61%), Asymmetry Capital Management L.P. (0.53%) and Tekla Capital Management LLC (0.40%). Company insiders that own Magenta Therapeutics stock include Bruce Booth, Jason Gardner, John C Davis Jr and Michael P Cooke. View institutional ownership trends for Magenta Therapeutics. Which institutional investors are selling Magenta Therapeutics stock? MGTA stock was sold by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Ensign Peak Advisors Inc, Marshall Wace North America L.P., FMR LLC, FMR LLC, Platinum Investment Management Ltd., New York State Common Retirement Fund, and Bailard Inc.. Company insiders that have sold Magenta Therapeutics company stock in the last year include Jason Gardner, John C Davis Jr, and Michael P Cooke. View insider buying and selling activity for Magenta Therapeutics. Which institutional investors are buying Magenta Therapeutics stock? MGTA stock was bought by a variety of institutional investors in the last quarter, including Artal Group S.A., Luminus Management LLC, Gilder Gagnon Howe & Co. LLC, Asymmetry Capital Management L.P., Tekla Capital Management LLC, Prosight Management LP, Marshall Wace LLP, and Monashee Investment Management LLC. View insider buying and selling activity for Magenta Therapeutics. How do I buy shares of Magenta Therapeutics? Shares of MGTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Magenta Therapeutics' stock price today? One share of MGTA stock can currently be purchased for approximately $7.72. How big of a company is Magenta Therapeutics? Magenta Therapeutics has a market capitalization of $372.51 million. The company earns $-76,770,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. Magenta Therapeutics employs 59 workers across the globe. What is Magenta Therapeutics' official website? The official website for Magenta Therapeutics is www.magentatx.com. How can I contact Magenta Therapeutics? Magenta Therapeutics' mailing address is 100 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-242-0170 or via email at [email protected] This page was last updated on 9/20/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
